Literature DB >> 16327028

Fxr(-/-) mice adapt to biliary obstruction by enhanced phase I detoxification and renal elimination of bile acids.

Hanns-Ulrich Marschall1, Martin Wagner, Karl Bodin, Gernot Zollner, Peter Fickert, Judith Gumhold, Dagmar Silbert, Andrea Fuchsbichler, Jan Sjövall, Michael Trauner.   

Abstract

Farnesoid X receptor knockout (Fxr(-/-)) mice cannot upregulate the bile salt export pump in bile acid loading or cholestatic conditions. To investigate whether Fxr(-/-) mice differ in bile acid detoxification compared with wild-type mice, we performed a comprehensive analysis of bile acids extracted from liver, bile, serum, and urine of naive and common bile duct-ligated wild-type and Fxr(-/-) mice using electrospray and gas chromatography mass spectrometry. In addition, hepatic and renal gene expression levels of Cyp2b10 and Cyp3a11, and protein expression levels of putative renal bile acid-transporting proteins, were investigated. We found significantly enhanced hepatic bile acid hydroxylation in Fxr(-/-) mice, in particular hydroxylations of cholic acid in the 1beta, 2beta, 4beta, 6alpha, 6beta, 22, or 23 position and a significantly enhanced excretion of these metabolites in urine. The gene expression level of Cyp3a11 was increased in the liver of Fxr(-/-) mice, whereas the protein expression levels of multidrug resistance-related protein 4 (Mrp4) were increased in kidneys of both genotypes during common bile duct ligation. In conclusion, Fxr(-/-) mice detoxify accumulating bile acids in the liver by enhanced hydroxylation reactions probably catalyzed by Cyp3a11. The metabolites formed were excreted into urine, most likely with the participation of Mrp4.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16327028     DOI: 10.1194/jlr.M500427-JLR200

Source DB:  PubMed          Journal:  J Lipid Res        ISSN: 0022-2275            Impact factor:   5.922


  42 in total

1.  Sirtuin 1 activation alleviates cholestatic liver injury in a cholic acid-fed mouse model of cholestasis.

Authors:  Supriya R Kulkarni; Carol J Soroka; Lee R Hagey; James L Boyer
Journal:  Hepatology       Date:  2016-10-28       Impact factor: 17.425

2.  Quantitative-profiling of bile acids and their conjugates in mouse liver, bile, plasma, and urine using LC-MS/MS.

Authors:  Yazen Alnouti; Iván L Csanaky; Curtis D Klaassen
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2008-09-03       Impact factor: 3.205

Review 3.  Drug disposition alterations in liver disease: extrahepatic effects in cholestasis and nonalcoholic steatohepatitis.

Authors:  Mark J Canet; Nathan J Cherrington
Journal:  Expert Opin Drug Metab Toxicol       Date:  2014-07-03       Impact factor: 4.481

4.  Will the real bile acid sulfotransferase please stand up? Identification of Sult2a8 as a major hepatic bile acid sulfonating enzyme in mice.

Authors:  Paul A Dawson; Kenneth D R Setchell
Journal:  J Lipid Res       Date:  2017-04-28       Impact factor: 5.922

Review 5.  FXR and PXR: potential therapeutic targets in cholestasis.

Authors:  Johan W Jonker; Christopher Liddle; Michael Downes
Journal:  J Steroid Biochem Mol Biol       Date:  2011-07-20       Impact factor: 4.292

6.  Nod2 deficiency protects mice from cholestatic liver disease by increasing renal excretion of bile acids.

Authors:  Lirui Wang; Phillipp Hartmann; Michael Haimerl; Sai P Bathena; Christopher Sjöwall; Sven Almer; Yazen Alnouti; Alan F Hofmann; Bernd Schnabl
Journal:  J Hepatol       Date:  2014-02-19       Impact factor: 25.083

7.  Lithocholic acid disrupts phospholipid and sphingolipid homeostasis leading to cholestasis in mice.

Authors:  Tsutomu Matsubara; Naoki Tanaka; Andrew D Patterson; Joo-Youn Cho; Kristopher W Krausz; Frank J Gonzalez
Journal:  Hepatology       Date:  2011-04       Impact factor: 17.425

8.  Mechanisms of resistance of hepatocyte retinoid X receptor alpha-null mice to WY-14,643-induced hepatocyte proliferation and cholestasis.

Authors:  Maxwell Afari Gyamfi; Yu-Jui Yvonne Wan
Journal:  J Biol Chem       Date:  2009-01-27       Impact factor: 5.157

9.  Urinary metabolomics in Fxr-null mice reveals activated adaptive metabolic pathways upon bile acid challenge.

Authors:  Joo-Youn Cho; Tsutomu Matsubara; Dong Wook Kang; Sung-Hoon Ahn; Kristopher W Krausz; Jeffrey R Idle; Hans Luecke; Frank J Gonzalez
Journal:  J Lipid Res       Date:  2009-11-09       Impact factor: 5.922

Review 10.  Novel insight into mechanisms of cholestatic liver injury.

Authors:  Benjamin L Woolbright; Hartmut Jaeschke
Journal:  World J Gastroenterol       Date:  2012-09-28       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.